It has been reported however that the approach does not constitute a formal proposal and the two companies are not currently in talks. However, Sanofi’s CEO Chris Viehbacher is reportedly considering using the company’s cash to partake in acquisitions in a bid to secure revenues as the patents on their existing drugs are set to expire.
The majority of Genzyme’s focus lies with orphan drugs – those which are used to treat rare conditions which affect a very small percentage of the population. These drugs there for come with high price tags – an attractive prospect for Sanofi.
Are you looking for a job in the pharmaceutical or biotechnology industry? Click here to search our current pharmaceutical and biotechnology jobs.